Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 9, No. 6, 617-632, November 2004; doi:10.1634/theoncologist.9-6-617
© 2004 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bernard-Marty, C.
Right arrow Articles by Piccart, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bernard-Marty, C.
Right arrow Articles by Piccart, M. J.

Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer

Chantal Bernard-Marty, Fatima Cardoso, Martine J. Piccart

Jules Bordet Institute, Brussels, Belgium

Correspondence: Martine J. Piccart, M.D., Ph.D., Department of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo, 125, 1000 Brussels, Belgium. Telephone: 32-2-541-32-06; Fax: 32-2-538-08-58; e-mail: martine.piccart{at}bordet.be

The management of metastatic breast cancer remains an important and controversial issue. The systemic therapy, comprising endocrine, cytotoxic and biological agents, can be administered sequentially or in combination. Few drugs or combinations provide a significant improvement in survival and, therefore, in the great majority of cases, treatment is given with a palliative intent. With the exception of first-line therapy, for which general agreement exists, currently there is no consensual standard of care. This review will summarize the current knowledge and outline the controversial issues related to systemic therapy of metastatic breast cancer, with emphasis on treatment tailoring. The potential role of tumor molecular profile(s) in the selection of patients that could benefit the most from each strategy/agent will be discussed.

Key Words. Breast cancer • Endocrine therapy • Chemotherapy • Biological therapy • Tailoring therapy




This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
J. M. Hall, M. A. Barhoover, D. Kazmin, D. P. McDonnell, W. F. Greenlee, and R. S. Thomas
Activation of the Aryl-Hydrocarbon Receptor Inhibits Invasive and Metastatic Features of Human Breast Cancer Cells and Promotes Breast Cancer Cell Differentiation
Mol. Endocrinol., February 1, 2010; 24(2): 359 - 369.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
L. Boehnke Michaud
The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer
Journal of Oncology Pharmacy Practice, June 1, 2009; 15(2): 95 - 106.
[Abstract] [PDF]

Home page
 JCOHome page
R. Le Scodan, D. Stevens, E. Brain, J. L. Floiras, C. Cohen-Solal, B. De La Lande, M. Tubiana-Hulin, S. Yacoub, M. Gutierrez, D. Ali, et al.
Breast Cancer With Synchronous Metastases: Survival Impact of Exclusive Locoregional Radiotherapy
J. Clin. Oncol., March 20, 2009; 27(9): 1375 - 1381.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. S. Thomas, H. L. Gomez, R. K. Li, H.-C. Chung, L. E. Fein, V. F. Chan, J. Jassem, X. B. Pivot, J. V. Klimovsky, F. H. de Mendoza, et al.
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
J. Clin. Oncol., November 20, 2007; 25(33): 5210 - 5217.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. Cameron, R. Bell, M. Aapro, and C. Zielinski
What Are the Current Standards of Care and Recent Developments in the Management of Breast Cancer?
Oncologist, September 1, 2006; 11(suppl_1): 1 - 3.
[Full Text] [PDF]

Home page
 JCOHome page
E. Rapiti, H. M. Verkooijen, G. Vlastos, G. Fioretta, I. Neyroud-Caspar, A. P. Sappino, P. O. Chappuis, and C. Bouchardy
Complete Excision of Primary Breast Tumor Improves Survival of Patients With Metastatic Breast Cancer at Diagnosis
J. Clin. Oncol., June 20, 2006; 24(18): 2743 - 2749.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Kiewe, S. Hasmuller, S. Kahlert, M. Heinrigs, B. Rack, A. Marme, A. Korfel, M. Jager, H. Lindhofer, H. Sommer, et al.
Phase I Trial of the Trifunctional Anti-HER2 x Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer.
Clin. Cancer Res., May 15, 2006; 12(10): 3085 - 3091.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2004 by AlphaMed Press.
Advertisement